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ABSTRACT 
 
DNA methylation is an epigenetic modification involved in key physiological 
processes, including X chromosome inactivation, imprinting, and transcriptional 
regulation in higher eukaryotes. The methylation patterns are formed early in embryonic 
development and copied during somatic cell division by a family of enzymes known as 
DNA methyltransferases (DNMTs). Aberrant DNMT function contributes to 
hypermethylation of promoter CpG islands in tumor suppressor genes, and 
hypomethylation of repetitive sequences in the genome. These epigenetic changes play a 
significant role in various diseases. 
While there are three major DNMT isoforms, DNMT1, DNMT3a and DNMT3b, 
the degree of redundancy of function at specific locations in the genome is not well 
understood. We have performed genome wide DNA methylation and gene expression 
analysis using MBD-Seq and RNA-Seq respectively on genomic DNA obtained from a 
set of isogenic cell lines in which either DNMT1, DNMT3b, both or neither were 
genetically disrupted. Data from bisulfite sequencing was used to confirm methylation 
differences between these isogenic lines. These data revealed that while disruption of 
both DNMT1 and DNMT3b was required to prevent maintenance of methylation at most 
genomic sites, maintenance of methylation at some genomic regions could be abrogated 
by disruption of just DNMT1 or DNMT3b alone. We found that while DNMT3b was 
required for maintaining methylation particularly at many coding exons, DNMT1 was 
required for maintenance of methylation largely at putative promoter regions. 
Additionally, DNMT1’s methylating ability was independent of clonal selection, and 
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DNMT1 mediated methylation led to gene repression in a subset of genomic regions. 
Finally, we discovered that DNMT1 could also control gene expression in the absence of 
cis DNA methylation alterations, providing evidence that it could act as a direct 
transcriptional repressor for a subset of genes.  
Identifying DNMT1’s methylation dependent and independent roles in gene 
silencing is an important aspect of understanding cancer epigenetics. Our data help to 
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1.1 A Brief Overview of Epigenetics 
 
 
The human genome provides information in two forms: genetic and epigenetic. While the 
genetic information provides the blueprints for making all living organisms, the 
epigenetic information provides the instructions for carrying it out. Epigenetics is the 
manual on how, when, and where the genetic information should be used.  
 
In short, epigenetics is the study of heritable changes in gene expression that occur 
without change in DNA sequence. Epigenetic signals include DNA methylation, histone 
modifications such as acetylation, phosphorylation, and methylation, and incorporation of 
histone variants and non-coding RNAs. All these signals cooperate to modulate 
chromatin structure and determine the transcriptional activity of the genome. Epigenetics 
impacts many areas of scientific research, including somatic gene therapy [1], cloning 
[2], cancer biology [3], genomic imprinting [4], and developmental abnormalities [5, 6]. 
 
A focal point in research for the past two decades have been the three main, inter-related 
types of epigenetic inheritance: DNA methylation, genomic imprinting, and histone 
modification. Events such as X-chromosome inactivation and genomic imprinting were 
found to depend on molecular events such as methylation and histone hypoacetylation [7-
13]. The inheritance of these epigenetic states also depends on DNA methylation during 
cell division, another direct epigenetic mechanism for maintaining gene repression. The 
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epigenetic templates that control gene expression are transmitted to daughter cells 
independently of the DNA sequences. However, these metastable patterns can sometimes 
become abnormal both in fetal development and the normal aging process, contributing 
to the common cancer risk. Because of this, we aim to study as much about these 
processes as we can, in the hope of defeating this ‘Emperor of all maladies [14].’ 
 
1.2 DNA Methylation 
 
The major DNA modification involved in encoding epigenetic information in mammalian 
cells is DNA methylation, a reaction that involves the covalent addition of a methyl 
group to the 5-postion of cytosine. First discovered in calf thymus DNA in 1948 [15], 
DNA methylation has proven to be a key epigenetic process involved in the control of 
gene expression, regulation of parental imprinting [4], and stabilization of X-
chromosome inactivation [7-13]. It is also implicated in the development of the immune 
system [16], cellular reprogramming [17-19], and in brain function and behavior [20, 21]. 
Aberrant DNA methylation patterns are associated with several diseases, among them the 
initiation and progression of cancer [22-24].  
 
In mammals, DNA methylation occurs primarily in CG dinucleotides, though it 
occasionally is found in non-CG sites. There are approximately 56 million CG sites in the 
human genome, about 60-80% of which are methylated [25, 26]. Methylation patterns 
vary with cell types, with the largest deviations seen in embryonic stem cells [25]. Much 
of the CG sites have been depleted from the human genome in the course of evolution 
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due to the mutagenic property of the 5-methyl-cytosine base. However, there remain 
regions of CpG islands [27] where the ratio of observed to expected CpG is greater than 
0.65. These CpG islands are found in promoter regions of about 70% of human genes 
[28] and DNA methylation at these promoter regions leads to repression of gene activity 
[25, 26, 29]. In contrast, active genes usually show hypomethylation around the 
transcriptional start site and high levels of methylation in the gene body [30]. In addition, 
DNA methylation levels change slightly at splicing sites, with exons showing higher rates 
of methylation than introns [25, 30], suggesting a role for DNA methylation in splicing as 
well. 
 
DNA methylation is catalyzed by a group of proteins known as DNA methyltransferases 
(DNMTs). These enzymes catalyze the transfer of the methyl group from S-adenosyl-L-
methionine (SAM) to the C5 position of cytosine residues, creating 5-methylcytosine. 
Figure 1.1 depicts the reaction mechanism.  The methyl addition does not interfere with 
Watson Crick base pairing because it occurs in the major groove of DNA, where DNA-
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Figure 1.1: Mechanism of Action of DNA Methyltransferase. The reaction begins 
with the cytosine base flipped out of the DNA and inserted into the binding pocket of 
DNMT. The catalytic cysteine thiolate forms a transition state intermediate with the C6 
of cytosine. The resulting 4-5 enamine attacks the methyl group provided by S-
Adenosylmethionine (SAM). After addition of the methyl group to C5 of cytosine, a 
proton is abstracted from the 5 position leading to reformation of the 5,6 double bond and 
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1.3 DNA Methyltransferases: Form and Function 
 
Global DNA methylation patterns are established by a group of proteins known as DNA 
methyltransferases, or DNMTs. The mammalian DNMT family contains four active 
members: DNMT1, DNMT3a, DNMT3b, and an interacting protein DNMT3L. The 
initial methylation pattern is set by the DNMT3 family [31, 32], whose de novo activity 
is indicated by their ability to target both hemimethylated and unmethylated DNA [33, 
34]. After each round of DNA replication, the parental strand carries the original 
methylation marks while the daughter strand is unmethylated. This hemimethylated DNA 
is then targeted by a maintenance methyltransferase (DNMT1) that copies the 
methylation marks from the parental strand to the daughter strand. While DNMT1 has 
significant catalytic preference for methylated hemimethylated DNA, its catalytic activity 
at unmethylated DNA is only modestly decreased compared to that of DNMT3A and 
DNMT3b. Thus, DNMT1 may participate in both de novo and maintenance methylation. 
A fifth member, DNMT2, lacks an N-terminal regulatory domain and has the potential to 
methylate tRNA instead of DNA [35].  
 
 
Mammalian DNMTs are comprised of two parts: an N-terminal regulatory domain and a 
C-terminal catalytic domain. The N-terminal domain guides nuclear localization of the 
enzymes and mediates their interaction with other proteins, DNA, and chromatin. For 
instance, the N-terminal regulatory region of DNMT1 contains a proliferating cell nuclear 
antigen-binding domain (PBD), a nuclear localization signal (NLS), a cysteine-rich 
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ATRX zinc finger DNA-binding motif and a polybromo homology domain (PHD) 
targeting DNMT1 to the replication foci. Meanwhile, the smaller C-terminal part is the 
catalytic center of the enzyme (Figure 1.2) [36].  
 
DNMT1 is the most abundant methyltransferase [37] involved in maintenance 
methylation [38, 39]. DNMT1 shows a preference for hemimethylated DNA and is 
localized at the DNA replication fork during S phase [40]. It is a highly processive 
enzyme, able to catalyze multiple reactions before dissociating from the DNA template 
[41], a property that fits well with its function at the replication fork. It is also the most 
abundant methyltransferase in somatic cells [42]. DNMT1 is essential to development, as 
its disruption results in extensive demethylation of the genome and embryonic lethality in 
mice [5]. As previously discussed, mutations in DNMT1 or its loss leads to alterations  
imprinting [4] and in X-chromosome inactivation [7-13], suggesting that DNMT1 is 
required for the maintenance of imprinting signals and stable X-chromosome 
inactivation. Disruption of DNMT1 in human colorectal carcinoma cells results in loss of 
proliferation and severe mitotic defects, followed by cell death [43]. Furthermore, 
DNMT1 loss of function is directly linked to tumorigenesis, as demonstrated in the 
finding that mice with depleted levels of DNMT1 are susceptible to tumors and display 
chromosomal instability [44, 45]. These represent just a small sampling of the gene 
targeting studies that have been done on this protein. Even so, one can already see that 
DNMT1 plays a crucial role in mammalian development, cell proliferation, and survival. 
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The Dnmt3 protein family comprises of 3 members: Dnmt3a, Dnmt3b, and Dnmt3L. 
DNMT3a and DNMT3b are known as de novo methyltransferases because they have an 
equal preference for hemimethylated and unmethylated DNA substrates [33, 34]. They 
are responsible for establishing methylation patterns early in mammalian development 
and in germ cells, and are essential to embryonic development in mice [46]. DNMT3b 
knockout mouse embryos die in utero and DNMT3a knockout mice die shortly after 
birth, revealing that disruption of any active DNMT is lethal. Mutations in human 
DNMT3b also causes ICF syndrome [47], a condition characterized by 
immunodeficiency, facial defects, and chromosomal abnormalities. 
 
Possessing homology to DNMT3a and DNMT3b, DNM3L serves as structural support 
for its de novo siblings. Although DNMT3L lacks its own catalytic activity, it is able to 
stimulate the activity of DNMT3a/3b in vivo by increasing their ability to bind to the 
methyl group donor, S-adenosyl-L-methionine (SAM) [48]. DNMT3L is thought to be 
expressed largely during gametogenesis and during various embryonic stages [49]. 
 
Cooperation among the DNMTs is required for maintaining methylation in certain 
genomic regions. Historically, DNMT1 has always been known as the maintenance 
methyltransferase, while DNMT3a and DNMT3b act as de novo enzymes. However, 
recent evidence indicates that DNMT1 may also be required for de novo methylation of 
genomic DNA [50, 51], and that the DNMT3 family members contribute to maintaining 
methylation during replication [52, 53].  
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Figure 1.2: Schematic of Mammalian DNMT Family Members*. Functional 
domains in the N-terminal part of the proteins are shown and the conserved C5 DNA 








*  Figure adapted from: R Villa, F De Santis, A Gutierrez, S Minucci, P.G Pelicci, L Di 
Croce, Epigenetic gene silencing in acute promyelocytic leukemia, Biochemical 
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1.4 Aberrant methylation in cancer 
 
In 1993, Holliday et al first indicated that DNA methylation could be an epigenetic 
mechanism for carcinogenesis [54]. Today, it is widely accepted that abnormal silencing 
of genes in cancer cells is mediated by aberrant methylation patterns. Specifically, 
methylation of CpG islands in gene promoter regions, coupled with gene body 
hypomethylation is associated with transcriptional silencing in tumor suppressor genes 
[23, 55, 56]. Promoter regions, normally hypomethylated, allow for an open chromatin 
configuration that permits easy access by transcription factors and RNA polymerase II to 
bind to the promoter and facilitate gene expression. In contrast, the hypermethylated 
promoter regions in cancer cells blocks transcription factor binding. Furthermore, loss of 
CpG methylation within the gene body in cancer cells causes loss of imprinting of genes 
and chromosomal instability, leading to tumorigenesis. Many genes modified by 
promoter hypermethylation have tumor suppressor function. Examples include the VHL 
gene in renal cancer, the cell cycle control gene p16 in many cancers, and the mismatch 
repair gene MLH1 in colorectal cancer [57, 58].  
 
In cancer cells, DNMT1 seems to be responsible for most of the DNA methylating 
capacity [59, 60]. In mouse models, DNMT1 is critical for development of intestinal 
polyposis, and disruption of the DNMT1 gene drastically reduces the incidence of tumors 
[61, 62]. Recent studies also suggest an interaction between DNMT1 and DNMT3b in 
colon cancer cells [59, 60], and that DNMTs may contribute to transcriptionally 
repressive chromatin by mechanisms other than methylation by forming complexes in the 
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promoter regions with groups of proteins that act to prevent the transcription of genes 
[63-69].  
 
In prostate cancer, transformation of normal prostatic epithelium to invasive 
adenocarcinoma can begin at early precursor states called PIA and PIN [70-72]. PIA and 
PIN lesions begin to exhibit hypermethylation in CpG island sequences of GSTP1, a 
protein that encodes a single class of glutathione S-transferases that attenuates the 
development of cancer upon exposure to carcinogens [73]. Hypermethylation increases as 
prostate cancer progresses, suggesting that chronic or recurrent inflammation may play a 
role in de novo acquisition of DNA methylation patterns. 
 
Because of the strong association between aberrant methylation and carcinogenesis, 
much research has focused on elucidating the factors that control DNA methylation. 
Understanding how DNMTs set up and maintain methylation patterns is a crucial part of 
the process. While the basic function of DNMTs has been revealed over time, the 
mechanism by which their activity is modulated is still unclear. For instance, do 
individual DNMTs act alone or cooperatively? Which parts of the genome do they target? 
Can DNMTs mediate gene expression independent of methylation? This dissertation 
explores the roles of DNMT1 and DNMT3b in maintaining DNA methylation patterns, 
and explores evidence suggesting that DNMT1 can mediate gene repression independent 
of its DNA methylation activity. 
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Three DNMTs are known to participate in generating and maintaining DNA methylation 
patterns: DNMT1, DNMT3a, and DNMT3b. Aberrant expression of these DNMTs 
disrupts normal methylation patterns and is closely associated with many forms of 
disease. For instance, hypermethylation at promoter CpG islands can lead to 
transcriptional silencing of key cellular pathways. In prostate cancer, methylation of the 
CpG-rich promoter region of GSTP1 is very common, and is one among many other 
hypermethylated genes [70-73]. These aberrant methylation patterns have also been 
linked to almost all other known cancer types including colorectal, breast, and lung 
cancers [74], suggesting that epigenetic silencing tumor suppressor and caretaker genes is 
an important contributor to the development of cancer. Meanwhile, inhibition of DNMTs 
correlates with reduction in tumorigenicity and increased expression of tumor suppressor 
genes [75]. Therefore, an in depth knowledge of how these methylation patterns are 
established and maintained is a vital step that can lead to disease treatment and diagnostic 
strategies.  
 
Various methods for genome-wide analysis of DNA methylation have been developed 
and utilized. Popular tools for differentiating methylated from unmethylated DNA 
include the use of sodium bisulfite modification, methylation sensitive and specific 
restriction enzymes (HpaII and McrBcI, respectively), an anti-5mC antibody, or methyl-
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binding domain (MBD) polypeptides [76]. These approaches have been successfully used 
in our lab and others to generate methylation profiles of various normal and cancer cell 
lines [77-79]. In particular, affinity based strategies like the use of MBD polypeptides are 
attractive because they are not limited to specific sequences, generate a positive signal for 
methylation, and are highly effective in separating unmethylated from methylated DNA 
[80, 81]. MBD polypeptides can also recognize 5-methyl-C in double stranded DNA, 
which, when combined with next generation sequencing [106], allowed us to generate 
global methylome profiles of a cancer cell line model with targeted disruption of DNMT1 
and DNMT3b.  
 
While the functions of DNMT1, DNMT3a, and DNMT3b have been the subject of muc 
research, there is still much unknown about their roles in mediating methylation of 
distinct genome compartments. In order to elucidate the role of DNMTs in genome 
methylation, we sought to determine how such methylation patterns can be affected by 
targeted genetic disruption of certain DNMTs. Using MBD-seq, we took isolated DNA 
from a set of HCT116 isogenic cell lines [59, 60], and subjected them to MBD based 
enrichment followed by next-generation sequencing. The following cell lines were used: 
HCT116-WT, HCT116-DNMT1-/-, HCT116-DNMT3b-/-, and HCT116-DNMT1-/-
DNMT3b-/- (DKO). The use of MBD-seq allowed us to develop genome-wide maps of 
methylated regions in each of these cell models and to identify regions of altered 
methylation in each of the DNMT knockout cells compared to the HCT116-WT parental 
cells. By comparing the methylation profile of the four HCT116 cell lines, we found 
regions of differential methylation mediated by one or more DNMTs. These methylomes 
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provide the foundation for which we examine the role of DNMT1 in the genome. In the 
following chapter, we will discuss the requirement of DNMT1 and DNMT3b in 
maintaining methylation at various genomic regions, and examine if DNMT1 dependent 
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2.2 MATERIALS AND METHODS 
 
2.2.1 Cell Culture 
 
Experiments were performed using a colorectal carcinoma line, HCT116, in which 
DNMT1, DNMT3b or both or neither were genetically disrupted. All cell lines were 
grown in McCoy’s medium with 10% FBS at 37 degrees.  
 
2.2.2 siRNA Treatment 
  
Cells were grown in 6 well plates and treated with 25nM of a siRNA pool (4) targeted to 
DNMT1 (Qiagen) every 24hrs for 72hrs. Cells were harvested 24hrs after the last 
transfection. McCoy’s serum free media was added to cells immediately prior to 
transfection. A transfection complex composed of Lipofectamine 2000, siDNMT1, and 
Optimem made according to the manufacturer’s protocol were allowed to sit at room 
temperature for 20 minutes before being applied to cells in serum free media. Five hours 
later, transfection complexes were removed and the medium was replaced with McCoy’s 
medium with 10% FBS.  
 
2.2.3 Decitabine Treatment 
 
Decitabine, or 5-aza-2-deoxycytidine (Sigma) was dissolved in DMSO immediately prior 
to use. Five concentrations (50nM, 100nM, 250nM, 500nM, and 1µM) of Decitabine 
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were added to cells seeded 24hrs prior in McCoy’s medium with 10% FBS. Cells were 




A schematic of the protocol is diagrammed in Figure 2.1. Two micrograms of genomic 
DNA from HCT116-WT, HCT116-DNMT1-/-, HCT116-DNMT3b-/- and HCT116-DKO 
were sonicated to a modal size of ~150–250 bp, and end-repaired using the NEBNext 
SOLiD DNA library preparation kit end-repair module following the manufacturer's 
protocol (New England Biolabs).  After column-purification (using the Qiagen PCR 
purification kit), SOLiD P1 and P2 adapters lacking 5′ phospate groups (Life 
Technologies) were ligated using the NEBNext adaptor ligation module, column-
purified, and treated with Platinum Taq polymerase for nick translation. The resulting 
library was divided into two fractions, a total input fraction, and an enriched methylated 
fraction. The methylated DNA was separated from unmethylated DNA in the enriched 
fraction by affinity enrichment of methylated DNA fragments using 6xHis-MBD2-MBD 
polypeptides immobilized on magnetic beads as described previously [77, 82]. 
 
The resulting enriched methylated fraction and the total input fraction were then 
subjected to library amplification using the NEBNext amplification module according to 
the manufacturer’s protocols. Library fragments that were between 200–300 bp were size 
selected after agarose gel electrophoresis. The libraries were then subjected to emulsion 
PCR and bead enrichment following the SOLiD emulsion PCR protocol (Life 
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Technologies). The resulting beads were then deposited on the SOLiD flow cell and 
subjected to massively parallel 50 bp single-read sequencing on a SOLiD v4.0 sequencer 
octet segment, with one octet segment for the total input and another one for the enriched 
methylated fraction. The resulting reads were mapped to hg18, and peaks of reads were 
called using the MACS program [83]. This allowed us to identify the methylated regions 
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2.2.5 RNA-Sequencing 
 
Total RNA was extracted from HCT116 isogenic cell lines using the RNeasy Kit from 
Qiagen. Approximately 1µg of total RNA from each cell line was prepared for 
sequencing using the TruSeq Stranded Total RNA Sample Preparation kit (Illumina) 
following manufacturer’s protocols. The resulting cDNA libraries were run on the 
Illumina HS200 platform for 200 cycles with 100bp by 100bp paired end reads. Reads 
were mapped to hg18 using RSEM. 
 
2.2.6 Analysis of Differentially Methylated Regions 
 
BAM files generated from MBD-seq were loaded into the Integrative Genomic Viewer 
[84, 85] to visualize the location of methylated peaks in the genome. CEAS software [86, 
87] was used to calculate the fraction of identified methylated and differentially 
methylated regions overlapping with various genome annotations (introns, exons, 5' gene 
upstream, 3' gene downstream, distal intergenic).  
 
2.2.6 Bisulfite Sequencing 
 
Bisulfite sequencing was used to detect the presence of methylated genomic regions of 
interest. This method involves conversion of unmethylated cytosines on CpG sites to 
uracils, while methylated cytosines remain unchanged. After PCR amplification, uracils 
are read as thymidines, and all cytosines present represent methylated cytosines. 
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Genomic DNA from a set of isogenic cell lines (HCT116, HCT116-DNMT1-/-, HCT116-
DNMT3b-/-, HCT116-DNMT1-/- DNMT3b-/-) was bisulfite converted using the EZ DNA 
Methylation Gold kit (Zymo). Converted DNA was subject to PCR amplification with a 
set of primers designed to genomic CpG islands of interest. The following cycling 
conditions were used: 95 °C for 3 minutes, 38 cycles of 95 °C for 30 seconds, 56 °C for 
30 seconds, 72 °C for 45 seconds, and 72 °C for 3 minutes. PCR products were run on 
2% agarose gel and excised and purified using the Zymoclean Gel DNA Recovery Kit 
(Zymo). After recovery, the DNA was cloned into TOP 10 competent cells using the 
TOPO TA cloning kit (Invitrogen) and manufacturer’s protocol. Between 50-100µl of 
cells were plated on Kanamycin-containing plates. Positive clones were selected for 
Sanger sequencing. The data obtained were used to compare methylation differences 
among the HCT116 wild type and knock out cell lines.  
 
2.2.7 Chromatin Immunoprecipitation (ChIP) 
 
Localization of DNMT1 to genomic regions of interest was determined by chromatin 
immunoprecipitation. HCT116-WT, HCT116-DNMT1-/-, HCT116-DNMT3b-/-, 
HCT116-DKO cells are treated with 1% formaldehyde to crosslink chromatin proteins to 
DNA. Cells were lysed and sonicated to shear DNA into small 300bp fragments. A small 
sample was set aside as the input fraction. Antibodies against DNMT1 (Sigma) was 
applied to the remaining sonicated sample and allowed to incubate overnight at 4°C. 
30µL per sample of Protein G Dynabeads (Invitrogen) was blocked in PBS BSA 
(5mg/mL), supplemented with yeast tRNA, and incubated overnight at 4°C. The next 
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day, the blocked bead solution was combined with the antibody-DNA solution and 
incubated for 4 hours. Bead bound immunocomplexes were precipitated by magnet and 
washed. Isolated antibody-chromatin complexes and the input fraction (non-
immunoprecipiated materials) were treated to remove the crosslink and the DNA is 
purified. Quantitative PCR with primers against CpG island regions of interest was used 
to amplify and detect the DNMT1 bound DNA.   
  
2.2.8 Quantitative RT-PCR 
 
RNA was isolated from all 4 HCT116 cell lines with the Qiagen All-Prep kit. 1µg of 
RNA was converted to cDNA with the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems). 10ng/µL of the resulting cDNA was used as the template for real-
time PCR. Gene expression was detected by quantitative RT-PCR using EVA Green 
qPCR master mix (Biotium) on Biorad iCycler thermal cyclers under the following 
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2.3 RESULTS 
 
2.3.1 Genomic DNA methylation patterns established with MBD-sequencing 
 
In order to examine the role of DNMT1 and DNMT3b in establishing/maintaining 
genome-wide methylation patterns, we used a set of HCT116 isogenic cell lines in which 
DNMT1, DNMT3b, or both or neither were genetically disrupted [59, 60] (figure 2.2). 
HCT116, a colorectal carcinoma line, exhibits hypermethylation associated gene 
silencing at hundreds of genes. DNA was isolated from each of the 4 lines (HCT116, 
HCT116-DNMT1-/-, HCT116-DNMT3b-/-, HCT116-DNMT1-/- DNMT3b-/-) and 
sequenced by MBD-seq. CEAS software [86, 87] was used to display methylation 
profiles and enrichment at important genomic features. The distribution of methylated 
regions by chromosome was generated for all 4 isogenic HCT116 cell lines. While 
HCT116-WT, HCT116-DNMT1-/- and HCT116-DNMT3b-/- cells showed similar levels 
of methylation across the genome, a substantial drop in methylated peaks was observed in 
HCT116-DKO (figures 2.3-2.6). Comparing the percent of methylated regions in each 
chromosome to the genome background (hg18), we observed that methylated regions are 
enriched in chromosomes 16, 17, 19, and 22 across all HCT116 cell lines. Additionally, 
methylated regions in HCT116-DKO were also enriched in chromosome 6. The 
distribution of methylated regions across important genomic features is depicted in a 
series of pie charts. While 8-9% of methylated regions occur in promoter sites of 
HCT116-WT, HCT116-DNMT1-/- and HCT116-DNMT3b-/-, only 4% are present in 
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promoter sites of HCT116-DKO. These data indicate that DNMT1 and/or DNMT3b are 
needed to maintain methylation at gene promoters.  
 In the human genome, non-coding introns and intergenic regions account for 
>90% of sequences. Approximately 2.5% of the genome occurs in promoter sites, and 
1.9% in coding exons. Compared to this genomic background, HCT116-WT cells were 
significantly enriched for methylation at promoter and exonic regions (Table 2.1), and 
relatively depleted for methylation in intronic and distal intergenic regions. Similar 
changes were observed in HCT116-DNMT1-/- and HCT116-DNMT3b-/- (Table 2.2, 2.3). 
In HCT116-DKO, methylated regions were mostly enriched in coding exons (Table 2.4). 
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Figure 2.3: Methylation in HCT116-WT. (A) Distribution of methylated regions by 
chromosome. The red bars plot methlylation while the line graph illustrates the 
distribution of peak heights. (B) Percent of methylated regions in each chromosome. The 
blue bars represent the percentages of the whole mappable regions in the chromosome 
(genome background). The orange bars represent the percent of methylated regions as a 
fraction all methylated regions identified in HCT116-WT. P-values for the significance of 
the relative enrichment of methylated regions with respect to the genome background are 
shown in parenthesis next to the percentages of the orange bars. The sum of the blue bars 
or the sum of the orange bars is 100%. (C) Distribution of methylated regions across 
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Figure 2.4: Methylation in HCT116-DNMT1-/-. (A) Distribution of methylated regions 
by chromosome. The red bars plot methlylation while the line graph illustrates the 
distribution of peak heights. (B) Percent of methylated regions in each chromosome. The 
blue bars represent the percentages of the whole mappable regions in the chromosome 
(genome background). The orange bars represent the percent of methylated regions as a 
fraction all methylated regions identified in HCT116-DNMT1-/-. P-values for the 
significance of the relative enrichment of methylated regions with respect to the genome 
background are shown in parenthesis next to the percentages of the orange bars. The sum 
of the blue bars or the sum of the orange bars is 100%. (C) Distribution of methylated 
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Figure 2.5: Methylation in HCT116-DNMT3b-/-. (A) Distribution of methylated regions 
by chromosome. The red bars plot methlylation while the line graph illustrates the 
distribution of peak heights. (B) Percent of methylated regions in each chromosome. The 
blue bars represent the percentages of the whole mappable regions in the chromosome 
(genome background). The orange bars represent the percent of methylated regions as a 
fraction all methylated regions identified in HCT116-DNMT3b-/-. P-values for the 
significance of the relative enrichment of methylated regions with respect to the genome 
background are shown in parenthesis next to the percentages of the orange bars. The sum 
of the blue bars or the sum of the orange bars is 100%. (C) Distribution of methylated 
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Figure 2.6: Methylation in HCT116-DKO. (A) Distribution of methylated regions by 
chromosome. The red bars plot methlylation while the line graph illustrates the 
distribution of peak heights. (B) Percent of methylated regions in each chromosome. The 
blue bars represent the percentages of the whole mappable regions in the chromosome 
(genome background). The orange bars represent the percent of methylated regions as a 
fraction all methylated regions identified in HCT116-DKO. P-values for the significance 
of the relative enrichment of methylated regions with respect to the genome background 
are shown in parenthesis next to the percentages of the orange bars. The sum of the blue 
bars or the sum of the orange bars is 100%. (C) Distribution of methylated regions across 
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Table 2.1: Distribution of Methylated Regions in HCT116-WT Across Important 
Genomic Features. For each genomic feature, the percent of methylated regions in 
HCT116-WT is shown under the percent of methylated regions expected for the genome 
(hg18). The percent of methylated regions in each genomic feature were also calculated 
for the top 500 regions as well as those with p-values < 10^-10. ‘Distal Intergenic’ refers 
















	   33	  
Table 2.2: Distribution of Methylated Regions in HCT116-DNMT1-/- Across 
Important Genomic Features. For each genomic feature, the percent of methylated 
regions in HCT116-DNMT1-/- is shown under the percent of methylated regions 
expected for the genome (hg18). The percent of methylated regions in each genomic 
feature were also calculated for the top 500 regions as well as those with p-values < 10^-
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Table 2.3: Distribution of Methylated Regions in HCT116-DNMT3b-/- Across 
Important Genomic Features. For each genomic feature, the percent of methylated 
regions in HCT116-DNMT3b-/- is shown under the percent of methylated regions 
expected for the genome (hg18). The percent of methylated regions in each genomic 
feature were also calculated for the top 500 regions as well as those with p-values < 10^-
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Table 2.4: Distribution of Methylated Regions in HCT116-DKO Across Important 
Genomic Features. For each genomic feature, the percent of methylated regions in 
HCT116-DKO is shown under the percent of methylated regions expected for the 
genome (hg18). The percent of methylated regions in each genomic feature were also 
calculated for the top 500 regions as well as those with p-values < 10^-10. ‘Distal 
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2.3.2 DNMT1 and DNMT3b have both distinct and cooperative functions in 
maintaining methylation patterns. 
 
From MBD-sequencing, we identified over 15,000 regions of differential methylation. In 
3233 regions, we found DNMT1-dependent methylation, defined as regions where loss of 
DNMT1 alone is sufficient to produce loss of methylation marks. These DNMT1-
dependent methylated sites are concentrated in putative promoter regions (+/- 3000bp 
away from TSS) and gene body exons. 10% of the 3233 regions were observed in gene 
promoters, a value that increases to almost 14% in the top 500 observed hits (table 2.5). 
DNMT1 dependent regions were also enriched in coding exons, with a 5-fold increase 
from genome background. Average methylation profiles reveal a substantial drop in 
methylation around the transcriptional start sites in HCT116-DNMT1-/- cells as compared 
to the HCT116-WT control (figure 2.10). Taken together, these findings suggest that 
DNMT1 is required for maintaining methylation at a significant number of gene 
promoters and exons. A list of the top putative promoter regions exhibiting DNMT1 
mediated methylation is provided in Table 2.8.  
 
DNMT1 mediates loss of methylation in more regions than DNMT3b, as our results 
revealed only 1243 regions that displayed DNMT3b dependent methylation. These 
results can be visualized with methylome maps- revealing more regions of DNMT1 
mediated methylation than that of DNMT3b mediated methylation (figures 2.7a, 2.8a). 
Additionally, the majority of DNMT3b dependent regions are located in coding exons, 
with 16.5% enrichment in the top 500 hits as compared to the genome background of 
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1.9% (Table 2.6). DNMT3b does not seem to affect promoter methylation, as the average 
profile reveals DNMT3b-/- methylation patterns to be similar to that of HCT116-WT 
(figure 2.11).  
 
Finally, the bulk of differentially methylated regions (13,377) displayed hypomethylation 
in DKO only, indicating that loss of DNMT1 or DNMT3b alone does not affect the 
region’s hypermethylated state, but absence of both results in loss of methylation (figure 

















	   38	  






	   39	  
Figure 2.7: Loss of Methylation in HCT116-DNMT1-/-. Regions that are 
hypomethylated in HCT116-DNMT1-/- relative to the HCT116-WT are displayed. (A) 
Distribution of differentially methylated regions by chromosome. The red bars plot 
differentially methlylated regions while the line graph illustrates the distribution of peak 
heights. (B) Percent of differentially methylated regions in each chromosome. The blue 
bars represent the percentages of the whole mappable regions in the chromosome 
(genome background). The orange bars represent the percent of differentially methylated 
regions as a fraction all methylated regions identified in HCT116-WT. P-values for the 
significance of the relative enrichment of methylated regions with respect to the genome 
background are shown in parenthesis next to the percentages of the orange bars. The sum 
of the blue bars or the sum of the orange bars is 100%. (C) Distribution of differentially 
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Figure 2.8: Loss of Methylation in HCT116-DNMT3b-/-. Regions that are 
hypomethylated in HCT116-DNMT3b-/- relative to the HCT116-WT are displayed. (A) 
Distribution of differentially methylated regions by chromosome. The red bars plot 
differentially methlylated regions while the line graph illustrates the distribution of peak 
heights. (B) Percent of differentially methylated regions in each chromosome. The blue 
bars represent the percentages of the whole mappable regions in the chromosome 
(genome background). The orange bars represent the percent of differentially methylated 
regions as a fraction all methylated regions identified in HCT116-WT. P-values for the 
significance of the relative enrichment of methylated regions with respect to the genome 
background are shown in parenthesis next to the percentages of the orange bars. The sum 
of the blue bars or the sum of the orange bars is 100%. (C) Distribution of differentially 
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Figure 2.9: Hypomethylation in HCT116-DKO. Regions hypomethylated in HCT116-
DKO but hypermethylated in HCT116-WT, HCT116-DNMT1-/- and HCT116-DNMT3b-
/- are represented. (A) Distribution of hypomethylation by chromosome. The red bars plot 
hypomethylated regions while the line graph illustrates the distribution of peak heights. 
(B) Percent of hypomethylated regions in each chromosome. The blue bars represent the 
percentages of the whole mappable regions in the chromosome (genome background). 
The orange bars represent the percent of hypomethylated regions as a fraction all 
methylated regions identified in HCT116-WT. P-values for the significance of the 
relative enrichment of methylated regions with respect to the genome background are 
shown in parenthesis next to the percentages of the orange bars. The sum of the blue bars 
or the sum of the orange bars is 100%. (C) Distribution of hypomethylated regions across 
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Figure 2.10: Average Methylation Profile Near the Transcriptional Start Site (TSS) 
and Transcriptional Termination Site (TTS) for (A) HCT116-WT, (B) HCT116-
DNMT1-/-, (C) HCT116-DNMT3b-/-, and (D) HCT116-DKO. Average enrichment of 
methylated regions is shown for regions near the TSS and TTS. HCT116-DNMT1-/- cells 
show a slight dip in methylation after the TSS (B) as compared to WT (A). HCT116-
DNMT3b-/- cells show similar methylation levels near the TSS (C). HCT116-DKO 
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Table 2.5: Genomic Distribution of Differential Methylation in Regions Presenting 
DNMT1 dependent methylation. Regions hypermethylated in HCT116-WT but 
hypomethylated in HCT116-DNMT1-/- are represented.  For each genomic feature, the 
percent of differentially methylated regions is shown under the percent of methylated 
regions expected for the genome (hg18). The percent of differentially methylated regions 
in each genomic feature were also calculated for the top 500 regions as well as those with 
p-values < 10^-10. We observe that regions presenting DNMT1 dependent methylation are 
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Table 2.6: Genomic Distribution of Differential Methylation in Regions Presenting 
DNMT3b dependent methylation. Regions hypermethylated in HCT116-WT but 
hypomethylated in HCT116-DNMT3b-/- are represented.  For each genomic feature, the 
percent of differentially methylated regions is shown under the percent of methylated 
regions expected for the genome (hg18). The percent of differentially methylated regions 
in each genomic feature were also calculated for the top 500 regions as well as those with 
p-values < 10^-10.  ‘Distal Intergenic’ refers to regions that do not belong in any of the 
other genomic features. We observe that regions presenting DNMT3b dependent 
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Table 2.7:  Genomic Distribution of Differential Methylation in Regions 
Hypomethylated in HCT116-DKO. Regions hypomethylated in HCT116-DKO but 
hypermethylated in HCT116-WT, HCT116-DNMT1-/- and HCT116-DNMT3b-/- are 
represented. For each genomic feature, the percent of hypomethylated regions is shown 
under the percent of methylated regions expected for the genome (hg18). The percent of 
hypomethylated regions in each genomic feature were also calculated for the top 500 
regions as well as those with p-values < 10^-10.  ‘Distal Intergenic’ refers to regions that 
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ALKBH5 chr17:18027236-18030236 1144 downstream 1950.99 
HOXB8 chr17:44045954-44048954 153 contains 1531.43 
ARC chr8:143688698-143693800 1587 downstream 1213.7 
CBX8 chr17:75386026-75389026 2040 upstream 855.84 
EPM2AIP1 chr3:37007938-37010937 363 contains 829.96 
PURB chr7:44889489-44892489 497 contains 812.68 
LHX6 chr9:124029007-124032007 334 contains 788.06 
NT5DC2 chr3:52542863-52545862 228 contains 611.25 
LFNG chr7:2523317-2526316 793 downstream 557.51 
DNAJC22 chr12:48023494-48028650 1236 contains 555.03 
SKAP2 chr7:26869711-26872711 344 upstream 539.07 
PIM1 chr6:37245643-37248643 1243 downstream 498.34 
NTF3 chr12:5472734-5475734 675 downstream 494.73 
SKI chr1:2149391-2152391 897 downstream 493.59 
MN1 chr22:26524778-26527777 1210 downstream 493.28 
TEAD3 chr6:35572675-35575674 1334 upstream 489.78 
SACM1L chr3:45703535-45706534 724 upstream 483.07 
RET chr10:42891818-42894817 794 downstream 477.16 
TACC1 chr8:38763160-38766159 780 downstream 462.51 
ROPN1L chr5:10493882-10496881 372 contains 443.54 
SPOCK1 chr5:136860630-136863630 788 downstream 440.06 
NPAS4 chr11:65943948-65946947 396 contains 438.72 
PRKCE chr2:45731899-45734899 852 downstream 397.82 
GBGT1 chr9:135027574-135030574 49 contains 388.66 
TEKT4 chr2:94899959-94902959 500 contains 387.6 
ZNF540 chr19:42732715-42735714 66 contains 380.23 
MAN1C1 chr1:25815653-25818652 606 downstream 370.42 
VIM chr10:17310010-17313010 1246 downstream 369.82 
KIF2B chr17:49254416-49257416 678 contains 355.29 
MEIS2 chr15:35177311-35180310 80 contains 352.03 
ICAM1 chr19:10240718-10243717 300 contains 350.12 
CRISPLD1 chr8:76057363-76060363 535 contains 344.59 
BATF3 chr1:210939171-210942171 720 contains 342.39 
CENPB chr20:3712953-3715952 886 downstream 341.43 
ROBO3 chr11:124240032-124243032 1017 contains 338.69 
NR3C2 chr4:149583075-149586075 1452 upstream 337.5 
SCRT1 chr8:145528743-145531742 510 contains 332.93 
SMPD3 chr16:67037985-67040984 427 contains 322.5 
CYP26B1 chr2:72229071-72232071 2099 upstream 318.44 
HUNK chr21:32168282-32171282 2283 downstream 280.72 
IFFO1 chr12:6533303-6536302 689 contains 269.26 
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2.3.3 DNMT1 dependent methylation near gene TSS occurs independent of 
selection. 
 
Reads generated from MBD-sequencing were loaded into the Integrated Genomics 
Viewer (IGV), a visualization tool for exploration of genomic data sets.  Differentially 
methylated regions across all 4 HCT116 cell lines are represented by peaks of aligned 
reads in one or more cell lines with absence of peaks in one or more cell lines. Visual 
inspection of the top regions (p-value <10-10) yielded a subset of 500 genes that contained 
the most convincing DNMT1-dependent methylated regions. These regions were 
characterized by hypermethylation in DNMT1 containing cell lines and corresponding 
hypomethylation in DNMT1-/- lines. To substantiate the differential methylation 
patterns, bisulfite sequencing was performed on the top regions. Eight clones were 
sequenced for each region, and the results confirm that DNMT1 is necessary for 
maintaining methylation at these regions (figure 2.11).  
 
Hypermethylation in all cell lines except HCT116-DKO characterized the majority of 
identified regions. This indicates that DNMT1 and DNMT3b may have similar 
mechanisms of action in these regions and are likely to act redundantly to maintain 
methylation. These results were also validated in a subset of regions with bisulfite 
sequencing (figure 2.12).  
 
A major concern with the use of isogenic cell lines is clonal selection. Since each of these 
lines was generated from a single clone, the possibility remains that unselected clones 
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may have a different phenotype. To confirm that our observations were independent of 
selection, we knocked down DNMT1 in HCT116 via DNMT1 siRNA over a period of 4 
days. Isolated DNA from transfected cells was subjected to bisulfite sequencing analysis 
with primers specific to select regions of DNMT1-dependent methylation and select 
regions of DKO hypomethylation. The majority of clones in DNMT1 dependent regions 
showed at least 60% reduction in CpG methylation upon depletion of DNMT1, while 
clones in regions of DKO hypomethylation mostly retained their methylated status 
(figure 2.13).  Taken together, our results indicate that DNMT1 dependent methylation in 
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2.3.4 DNMT1 is directly bound to a subset of DNMT1 requiring regions 
 
Next we investigated whether DNMT1 may mediate methylation by binding to targeted 
regions. Chromatin immunoprecipitation for DNMT1 was performed on regions 
exhibiting DNMT1 mediated methylation. Results reveal that DNMT1 is bound to CpG 
islands in putative promoter regions in gene body exons but not bound to CpG islands 
located at introns (figure 2.14). These results suggest that DNMT1 acts directly on 
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2.3.5 DNMT1 dependent methylation is associated with gene repression 
 
Finally, we investigated whether DNMT1 mediates gene repression directly through 
DNA methylation. Gene expression profiles for all 4 HCT116 cell lines generated 
through RNA-seq were compared to the differentially methylated regions identified by 
MBD-seq. Table 2.9 displays a chart of the results. Among 77 differentially expressed 
genes identified through RNA-seq, 14 genes showed a negative correlation between 
methylation and expression. Genes were expressed in the absence of DNMT1 mediated 
methylation and repressed when DNMT1 was present, suggesting that DNMT1-
dependent methylation is associated with gene silencing. This is further supported by the 
fact that 78% of these regions are located at putative promoter sites, defined as any region 
within 3000bp of the transcriptional start site.  
 
Further analysis by quantitative RT-PCR confirmed our initial observations. Vimentin, 
one of our top hits, showed a 10-fold increase in expression in the absence of DNMT1. 
This result was corroborated by qRT-PCR, with HCT116-DNMT1-/- cells displaying an 
almost 60 fold change in expression when compared to housekeeping gene TBP. When 
DNMT1 in HCT116 was depleted through siRNA over a period of 7 days, Vimentin 
expression slowly recovered. Similarly, treatment of HCT116 cells with Decitabine 
showed a positive correlation between Decitabine concentration used and Vimentin gene 
expression (figure 2.15). All 14 genes identified displayed similar patterns of methylation 
dependent expression (figure 2.16). Therefore, these results as a whole provide strong 
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Table 2.9:     DNMT1 Mediated Methylation Can Control Gene Expression. Among 77 
differentially expressed genes identified through RNA-Seq, 14 regions showed a negative 
correlation with differential methylation. Differential methylation upstream (+) or 
downstream (-) of the transcriptional start site (TSS) is notated along with corresponding 
p-values and number of RNA-Seq reads. Additionally, approximately 78% (11 out of 14 
regions) of the regions are present in putative promoter sites (defined as residing within 























wt 1-/- 3b-/- dko to TSS P-value wt 1-/- 3b-/- dko wt 1-/- 3b-/- dko
EPM2AIP1 + + 363 829.96 34 112 21 83
VIM 1246 369.82 917 10774 235 4214
ARC 1587 1213.7 74 109 43 151
CYP26B1 2099 318.44 40 101 34 70
PTH1R 4839 314.85 10 37 10 33
NT5DC2 + + 228 611.25 203 303 195 358
ICAM1 300 350.12 111 234 10 368
BATF3 + + 720 342.39 60 133 41 95
IFFO1 689 269.26 10 29 10 41
NINJ2 19882 339.56 10 41 10 36
SAP25 + + 3327 178.97 16 527 10 1303
GBGT1 + + 49 388.66 10 10 10 34
HUNK 2283 280.72 10 10 10 36
PURB + + 497 812.68 113 184 110 142
(+) upstream, (-) downstream
Differential Methylation
(  indicates expression) (Number of Reads)
Differential Expression 
  To TSS P-value
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2.4 DISCUSSION AND CONCLUSIONS 
 
In this chapter we examined the methylation profile of a set of HCT116 isogenic cell 
lines. We found that DNMT1 was mostly responsible for promoter hypermethylation, 
while DNMT3b primarily methylated CpG islands in the gene body. This fact alone 
points to a distinct preference for DNMT1 and DNMT3b in distinct parts of the genome.  
 
We also observed numerous genomic regions that showed hypomethylation in HCT116-
DKO alone. These regions constitute the vast majority of our hits. We postulate that in 
these regions, DNMT1 and DNMT3b have similar mechanisms of action, acting 
redundantly to maintain methylation.  
 
Results from MBD-seq revealed that DNMT1 is most clearly responsible for differential 
methylation in the majority of regions where methylation depends on one 
methyltransferase. These DNMT1 requiring regions were mostly concentrated in 
promoter CpG islands, suggesting that DNMT1 mediated methylation is directly involved 
in gene silencing. DNMT1 was also shown to localize to regions of differential 
methylation, confirming its direct role in methylating these regions. Bisulfite sequencing 
of HCT116 transfected with siDNMT1 showed demethylation in clones corresponding to 
DNMT1 methylation dependent regions only, indicating that our observations are 
independent of clonal selection.  
DNMT1’s role in gene repression was confirmed when we compared our MBD-seq 
results to reads generated from RNA-seq of the four cell lines. For a subset of 14 genes, 
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we discovered that loss of methylation through loss of DNMT1 alone resulted in gene 
expression. When siDMT1 and Decitabine were used to transiently lower DNMT1 
expression, we saw a corresponding increase in gene expression. These findings point to 
a direct role for DNMT1 in gene silencing through promoter CpG hypermethylation.  
 
Interestingly, regions dependent on DNMT3b for methylation were much less prominent, 
and when they are present, are weaker hits than their DNMT1 dependent counterparts. 
This could suggest that while DNMT1 can mediate gene expression independent of other 
DNMTs, DNMT3b mostly works in conjunction with other methyltransferases. With the 
exception of the HCT116-DKO, which has a small residual amount of DNMT3a 
expression, all the cell lines overexpress DNMT3a, a protein that is already known to 
work in conjunction with DNMT3b as a de novo methyltransferase. Perhaps in certain 
genomic regions DNMT3a acts like a ‘backup’ methyltransferase in the absence of 
DNMT3b. Further research is needed to tease out these mechanisms.  
 
Examining our genome wide sequencing results as a whole, it becomes apparent that each 
DNMT does not have the same function in all genomic regions. The interplay between 
the proteins seems complex. While we have successfully elucidated a mechanism by 
which DNMT1 mediates gene repression, we also uncovered over 10,000 additional 
regions showing hypomethylation in HCT116-DKO alone. DNMT3a may play a greater 
role in these regions as well, covering for the function of DNMT1 or DNMT3b when 
they are absent. In the future, a closer examination through ChIP-seq may help determine 
the genomic localization of all the active mammalian methyltransferases.  
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In the preceding chapter, we discussed the role of DNMT1 in gene repression by 
methylating promoter CpG sites. However, it is possible that DNMT1 uses non-catalytic 
mechanisms of activity to modulate gene expression. The existence of functional roles for 
the N-terminal region of DNMT1 has been hinted at in the literature. For example, 
depletion of DNMT1 by antisense knockdown in A549 and HEK293 cells induces gene 
expression in a DNA methylation-independent mechanism [88]. DNMT1 was also found 
to activate Sp1 response elements independent of increased Sp1 expression, indicating 
that DNMT1 must be acting directly or indirectly on proteins interacting with Sp1 and 
modulating their trans-activation activity [88]. In a separate report, the N-terminal region 
of DNMT1 was also found to mediate E-Cadherin through its direct interaction with the 
E-cadherin transcriptional repressor SNAIL1 [89].  
 
DNMT1 has been well characterized as a maintenance methyltransferase that can mediate 
gene expression primarily through DNA methylation. However, evidence also suggests 
that DNMT1 mediated gene repression may not always be dependent on methylation. 
Treatment of some cells by a DNMT1 inhibitor 5-aza-2′-deoxycytidine (Decitabine), 
causes increases in expression of some genes without evident changes in DNA 
methylation [90, 91]. Since Decitabine treatment is also known to cause DNMT1 
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degradation [92, 93], the repressive ability of the protein at specific silenced and 
unmethylated genes may be due to a non-catalytic function of DNMT1 potentially 
associated with additional proteins, or through indirect secondary effects mediated by 
genes that are primarily demetylated and activiated by Decitabine. Additionally, DNMT1 
has been shown to modulate gene activity independent of its catalytic domain [94]. When 
a catalytically inactive DNMT1 was expressed in HCT116-DNMT1-/- cells, certain target 
genes were still repressed [95]. In the same publication, the histone demethylase LSD1 
was recruited by DNMT1 to specific promoters and partially mediated expression of 
these genes.  
 
In this chapter, we will identify genes for which DNMT1 acts as a transcriptional 
repressor independent of DNA methylation, and examine some of the complexities and 
additional work needed to more definitively test the hypotheses raised by the work 










	   66	  
3.2 Methods 
 
3.2.1 Transient expression of DNMT1 full length and mutant constructs 
 
The following DNMT1 full length and mutant constructs were previously generated by a 
member of our lab (Gangadharan S, unpublished): DNMT1 full length, C1226S, C670S, 
K1535A, C1001S, C664S, and C686S, where C----S denotes a cysteine to serine 
mutation at amino acid ----. 2µgs of DNMT1 full length or mutant construct was 
transfected into HCT116-DNMT1-/- cells with 6µL Lipofectamine 2000 (Invitrogen) 
resuspended in 100µL of Optimem (Life Technologies). Cells were plated at 60% 
confluency in 6-well tissue culture plates 24 hours prior to transfection. Growth media 
(McCoy’s + 10% FBS) was replaced with McCoy’s serum free media immediately prior 
to transfection. Lipid and DNA reagents were allowed to complex in Optimem at room 
temperature for 15 minutes before being added to cells. Five hours post transfection, 
complexes were removed and media changed to McCoy’s with 10% FBS. Cells were 
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3.3 Results 
 
3.3.1 DNMT1 can influence gene expression independent of methylation 
 
As described in Chapter II of this dissertation, RNA-seq was performed on HCT116-WT, 
HCT116-DNMT1-/-, HCT116-DNMT3b-/-, and HCT116-DKO and compared to the 
differentially methylated regions identified by MBD-seq (Table 3.1).  Our analysis 
identified a subset of genes that were activiated in DNMT1-/- compared to WT cells, but 
that did not show any change in methylation (either both methylated, or both 
unmethylated). For instance, while MAGEA4 showed absence of promoter methylation 
across all 4 HCT116 cell lines, disruption of DNMT1 in MAGEA4 precipitates an 
increase in MAGEA4 expression. These results were validated by quantitative RT-PCR. 
Furthermore, upon transient depletion of DNMT1 via RNAi or Decitabine, MAGEA4 
expression was restored, indicating that DNMT1 acts as a gene repressor independent of 
methylation activity (figure 3.1). In total, we confirmed 10 genes that displayed similar 
patterns of DNMT1 mediated, methylation independent repression (figure 3.2 for 
additional examples). 
 
Interestingly, we also identified two genes, TBX3 and FLNC, which were equally 
methylated in both the WT and DNMT-/- cells, but became transcriptionally activated in 
the absence of DNMT1 (figure 3.3 and 3.4). Quantitative RT-PCR confirmed the RNA-
seq results for both genes, and RNAi and Decitabine mediated depletion of DNMT1 led 
to expression of TBX3 and FLNC.  
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From the data set shown above, we hypothesized that DNMT1 may play a role in the 
direct repression of these genes independent of it catalytic activity. However, the 
mechanisms by which DNMT1 can mediate repression remains to be determined. 
 
Closer examination of DNMT1’s methylation independent role in gene control requires 
knowledge of its regulatory and catalytic domains. It is well known that that specificity of 
DNMT1 for methylation sites resides in its catalytic domain [94]. There is also evidence 
that suggests an autoinhibitory role for the RFTS domain in DNMT1 [96]. Additionally, 
there is emerging evidence that the CXXC domain of DNMT1 is essential for its 
enzymatic activity [97]. Taking these hints from literature, we developed a series of 
DNMT1 mutation constructs with the objective of asking which one of these constructs, 
when overexpressed in HCT116-DNMT1-/- cells, can rescue gene repression of the genes 
described above (Gangadharan S, unpublished). Failure to rescue would indicate that the 
particular mutated amino acid or deleted domain is important for mediated trans 
repression independent of methylation. A series of 9 DNMT1 mutant constructs were 
generated; DNMT1 full length, CXXC, C1226S (cysteine to serine mutation at amino 
acid 1226), C670S, K1535A, C1001S, C664S, and C686S (Figure 3.5). All mutant 
constructs were successfully transfected and overexpressed in HCT116-DNMT1-/- cells. 
 
Initially, when the mutant constructs were introduced into HCT116-DNMT1-/-, the 
results were promising. The full length DNMT1 as well as catalytically dead constructs 
repressed MAGEA4, while the vector control (TAP vector) behaved similarly to the 
HCT116-DNMT1-/- cells. There was even a slight increase in MAGEA4 expression with 
	   69	  
the C670S mutant construct, suggesting involvement of this cysteine in repression. 
However, subsequent experiments were plagued by variability. Data from 3 separate 
trials of 5 replicates each for the MAGEA4 gene are shown in (Figure 3.6). Not only did 
we observe variability between experiments, the standard error within each experiment 
covered a very broad range. We suspected that the variability could be attributed to 
differences in the levels of expression achieved in each experiment, and from this, we 
concluded that a different approach utilizing stable cell lines containing DNMT1 deletion 
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Table 3.1:     DNMT1 Influences Gene Expression Independent of Methylation. Two 
scenarios exist for methylation independent, DNMT1 mediated repression. (A) 
Methylation is present in both WT and HCT116-DNMT1-/-, and the gene is induced in 
HCT116-DNMT1-/- compared to WT,  or (B) Absence of methylation in both HCT116-



























wt 1-/- 3b-/- dko wt 1-/- 3b-/- dko wt 1-/- 3b-/- dko
TBX3 + + + + + 36 264 31 13
FLNC + + + + + 10 215 10 423
TXNIP + + 39 1601 10 235
PEG10 + + 22 1191 12 239
FN1 + + 35 393 26 22
HEY1 + + 27 65 29 14
CTCFL + + 10 207 10 443
MAGEA4 + + 95 2259 10 6677
ZNF704 + + 14 121 39 32
NXT2 + + 119 823 97 702
NOTUM + + 110 606 95 243
HCLS1 + + 99 390 80 314
Methylation Expression 
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3.4 Discussion and Conclusions 
 
 
Our genome wide profiles of methylation and gene expression reveal a set of genes 
repressed by DNMT1 independent of DNA methylation. We found a subset of  genes that 
were unmethylated in all cell lines, but selectively expressed upon DNMT1 disrupted 
cells. Transient depletion of DNMT1 through RNAi and Decitabine independently 
confirmed these results.  
 
The suggestion that DNMT1 has repressive functions independent of promoter 
hypermethylation points to a multifaceted role for DNMT1 in gene regulation. In order to 
understand the full role of this protein in gene expression control, we will have to 
examine how DNMT1 combines its transcriptional repression mechanism with DNA 
methyltransferase activity in gene silencing. This may be more complicated than it 
appears, as we have shown that DNMT1 mediates gene repression in varying ways in 
different regions of the genome.  A number of studies have shown that DNMT1 interacts 
directly with HDAC1 and HDAC2, indicating a role for DNMT1 as part of a repressive 
complex [65, 66, 68]. Furthermore, a recent study of tumor suppressor gene RASSF1A 
revealed that HBx promoted recruitment of DNMT1 to RASSF1A promoter regions, 
which occured independent of RASSF1A promoter methylation [98]. Therefore, one 
possible way DNMT1 may mediate methylation independent gene repression is through 
recruitment of other histone modifying proteins. 
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Initially, we hoped to identify the portion of DNMT1 responsible for methylation 
independent of gene repression by transiently transfecting a set of DNMT1 full length 
and mutant constructs into HCT116-DNMT1-/- cells. However, it became apparent that 
transient incorporation of mutant constructs produced variable and unreliable results. A 
likely explanation is that the short time frame for disruption is not sufficient for analysis 
of downstream effects. Inherent variations between experiments are also a possibility. 
Because each experiment involves numerous steps, anything from transfection reagent 
toxicity to variable RNA to cDNA conversion rates can cause significant variability in 
the final measures. Hence, it may be worthwhile to create a set of stable cell lines 
containing various truncated or mutated versions of DNMT1 knocked in to the 
endogenous locus, or inserted randomly in the genome. These cell lines may help identify 
which portion(s) of DNMT1 are responsible for methylation independent repression.   
  
Identifying DNMT1’s methylation independent role in gene control has translational 
implications. For instance, a number of cancer therapeutics have been developed to 
reverse abnormal gene silencing associated with hypermethylation in promoter CpG 
islands [99, 100]. DNA demethylating drugs such as 5-azacytidine and Decitabine (5-aza-
2′deoxycytidine) are popular drugs that block the catalytic function of DNMT1. 
However, inhibiting DNA methylation has also been shown to induce genes that promote 
metastasis [101-103]. Additionally, hypomethylation has also been shown to promote T 
cell lymphoma in mice hypomorphic for DNMT1 [45]. Therefore, if we can elucidate the 
mechanism by which DNMT1 mediates methylation independent gene repression, we can 
unlock new targets for chemotherapeutics.  
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Another potential improvement for chemotherapeutics can also occur through study of 
DNMT1’s gene repressive mechanisms. Treatment with Decitabine (5-aza-
2′deoxycytidine) and 5-azacytidine may also cause changes in gene expression that spans 
beyond genes regulated by DNA methylation alone. Further experiments that explore this 
























Identifying DNMTs’ methylation dependent and independent roles in gene silencing is an 
important aspect of epigenetic research. Historically, DNMTs have been widely 
implicated in methylation mediated gene regulation. As a result of extensive work in this 
field, various roles have been canonically assigned to each methyltransferase. While 
DNMT1 labeled as a maintenance methyltransferase, the DNMT3 family was implicated 
in de novo methylation. Our work helps to clarify the roles of the DNMT1 and DNMT3b 
methyltransferases in maintaining genome methylation patterns. We find that DNMT1 is 
required for promoter methylation and repression in a significant subset of genes and that 
DNMT3b is required for maintaining methylation at a number of coding exons. However, 
methylation of genomic regions by DNMTs appears mostly a redundant/cooperative 
effort- as the predominance of regions can lose their methylation only when both 
DNMT1 and DNMT3b are disrupted. 
 
The presence of genomic regions methylated in HCT116-DKO provides additional areas 
worthy of exploration. We observed a small subset of regions that were methylated in the 
absence of DNMT1 and DNMT3b. These results were not unexpected, as methylation 
profiles of the same clone of HCT116-DKO1 cells published earlier revealed a subset of 
hundreds of regions that still retained a high level of DNA methylation in these cells 
[104]. Since DNMT3a is still present in small amounts in HCT116-DKO, its role in these 
methylated sites may be worthy of exploration. Additionally, the HCT116-DNMT1 and 
HCT116-DKO cells used in the current and prior studies continue to retain and express a 
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hypomorphic isoform of DNMT1 with extremely reduced, yet measurable, catalytic 
activity [107]. Thus the residual methylation in the DKO cells may be partially 
maintained by this hypomorphic residual activity. 
 
Of all the DNMTs, DNMT1 appears most likely to play a major role in cancer 
development. The enzyme has been reported to be required for intestinal polyp 
development in ApcMin/+ mice and for tobacco carcinogen-induced murine lung cancer 
development in vivo [62, 105]. Low levels of DNMT1 can also result in cancer 
development. Mice carrying one disrupted DNMT1 allele and one hypomorphic DNMT1 
allele only retain 10% of normal DNMT activity, and are reported to exhibit genomic 
instability and to develop T-cell lymphomas [44, 45]. We have provided evidence that 
DNMT1 mediated promoter methylation appears solely responsible for gene repression in 
a number of genes. If aberrant DNMT1 activity is indeed an important precursor to 
carcinogenesis, our results indicate that DNMT1 methylation mediated gene silencing is 
one way the enzyme may contribute to cancer development. The interesting observation 
that specific regions of the genome require DNMT1 for maintenance of methylation 
suggests that such regions might be particularly prone for DNMT inhibitor based gene 
reactivation. Such knowledge may be helpful for developing strategies for 
pharmacodynamic tracking of DNMT inhibitor responses. 
 
It is only recently that DNMT1’s N-terminal activity was revealed in literature. In our 
studies, DNMT1’s methylation independent gene repression activity was discovered for 
several new genes. Identifying the portion(s) of DNMT1 responsible for gene repression 
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in this manner would open up new possibilities for targeting DNMT1. Although 
demethylating drugs such as Azacitidine and Decitabine have existed for numerous years, 
their use involves hematologic side effects that have limited the ability to create effective 
dosing regimens. Therefore, we hope our data paints a clearer portrait of DNMT1 
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